WO2009091932A3 - Treatment of mild dementia of the alzheimer's disease type - Google Patents

Treatment of mild dementia of the alzheimer's disease type Download PDF

Info

Publication number
WO2009091932A3
WO2009091932A3 PCT/US2009/031167 US2009031167W WO2009091932A3 WO 2009091932 A3 WO2009091932 A3 WO 2009091932A3 US 2009031167 W US2009031167 W US 2009031167W WO 2009091932 A3 WO2009091932 A3 WO 2009091932A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
treatment
disease type
mild dementia
mild
Prior art date
Application number
PCT/US2009/031167
Other languages
French (fr)
Other versions
WO2009091932A2 (en
Inventor
Paul Spence
Gregory T. Went
Timothy J. Fultz
Original Assignee
Adamas Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamas Pharmaceuticals, Inc. filed Critical Adamas Pharmaceuticals, Inc.
Publication of WO2009091932A2 publication Critical patent/WO2009091932A2/en
Publication of WO2009091932A3 publication Critical patent/WO2009091932A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods, compositions, and kits for slowing progression of Alzheimer's disease symptoms in a patient with mild Alzheimer's disease are described.
PCT/US2009/031167 2008-01-18 2009-01-15 Treatment of mild dementia of the alzheimer's disease type WO2009091932A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2228608P 2008-01-18 2008-01-18
US61/022,286 2008-01-18

Publications (2)

Publication Number Publication Date
WO2009091932A2 WO2009091932A2 (en) 2009-07-23
WO2009091932A3 true WO2009091932A3 (en) 2009-10-08

Family

ID=40885891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/031167 WO2009091932A2 (en) 2008-01-18 2009-01-15 Treatment of mild dementia of the alzheimer's disease type

Country Status (1)

Country Link
WO (1) WO2009091932A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1014793A2 (en) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc treatment of cognition disorders with certain alpha-7-nicotinic acid receptors in combination with acetyl cholinesterase inhibitors
WO2013151729A1 (en) * 2012-04-03 2013-10-10 Trustees Of Boston University Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254251A1 (en) * 2003-06-16 2004-12-16 Allergan, Inc. Memantine oral dosage forms
US20050203191A1 (en) * 2004-03-03 2005-09-15 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
US20060142398A1 (en) * 2004-11-23 2006-06-29 Went Gregory T Method and composition for adminstering an NMDA receptor antagonist to a subject
US20060198884A1 (en) * 2004-06-17 2006-09-07 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US20060252788A1 (en) * 2005-04-06 2006-11-09 Went Gregory T Methods and compositions for the treatment of CNS-related conditions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254251A1 (en) * 2003-06-16 2004-12-16 Allergan, Inc. Memantine oral dosage forms
US20050203191A1 (en) * 2004-03-03 2005-09-15 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
US20060198884A1 (en) * 2004-06-17 2006-09-07 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US20060142398A1 (en) * 2004-11-23 2006-06-29 Went Gregory T Method and composition for adminstering an NMDA receptor antagonist to a subject
US20060252788A1 (en) * 2005-04-06 2006-11-09 Went Gregory T Methods and compositions for the treatment of CNS-related conditions

Also Published As

Publication number Publication date
WO2009091932A2 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
WO2008089397A3 (en) Adrb2 cancer markers
WO2007092329A3 (en) Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
WO2009023509A3 (en) Therapeutic combinations useful in treating cftr related diseases
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2006127900A3 (en) Tl1a in the treatment of disease
MX2012004551A (en) Novel compositions for preventing and/or treating lysosomal storage disorders.
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
WO2009052439A3 (en) Immunotherapy regimes dependent on apoe status
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
WO2009155513A3 (en) Immunoglobulins with reduced aggregation
WO2006107745A3 (en) Composition for treatment of menopause
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2008106646A3 (en) Methods and formulations for topical gene therapy
WO2007007173A3 (en) Human anti-madcam antibodies
WO2008053444A3 (en) Treating a respiratory condition with bifidobacterium
WO2009149486A3 (en) Compounds for treating beta-amyloidoses
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2008066784A3 (en) Expression of foxp3 by cancer cells
WO2008027600A3 (en) Imatinib compositions
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09702813

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09702813

Country of ref document: EP

Kind code of ref document: A2